Compare APLE & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APLE | IRON |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 2007 | 2020 |
| Metric | APLE | IRON |
|---|---|---|
| Price | $15.95 | $68.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $13.00 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 2.3M | 458.0K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $1,238,622,000.00 | N/A |
| Revenue This Year | $2.31 | N/A |
| Revenue Next Year | $2.35 | $283.52 |
| P/E Ratio | $129.96 | ★ N/A |
| Revenue Growth | ★ 18.98 | N/A |
| 52 Week Low | $10.85 | $40.00 |
| 52 Week High | $15.81 | $99.50 |
| Indicator | APLE | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 77.51 | 49.18 |
| Support Level | $11.50 | $64.39 |
| Resistance Level | N/A | $71.53 |
| Average True Range (ATR) | 0.33 | 3.10 |
| MACD | 0.07 | -0.24 |
| Stochastic Oscillator | 96.78 | 43.74 |
Apple Hospitality REIT Inc is a real estate investment trust that invests in income-producing real estate, majorly in the lodging sector, in the United States. It chiefly invests in upscale service hotels. All of the company's hotels operate under the Marriott or Hilton brands. Apple Hospitality has wholly-owned taxable REIT subsidiaries, which lease all of the company's hotels from wholly-owned qualified REIT subsidiaries. These hotels are managed under separate agreements with various hotel management companies that are unaffiliated with Apple Hospitality. The company derives its income from hotel revenue, its sole segment.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.